2024
Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis.
Trujillo G, Regueiro-Ren A, Liu C, Hu B, Sun Y, Ahangari F, Fiorini V, Ishikawa G, Al Jumaily K, Khoury J, McGovern J, Lee C, Peng X, Pivarnik T, Sun H, Walia A, Woo S, Yu S, Antin-Ozerkis D, Sauler M, Kaminski N, Herzog E, Ryu C. Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2024 PMID: 39189851, DOI: 10.1164/rccm.202401-0065oc.Peer-Reviewed Original ResearchToll-like receptor 9Model of pulmonary fibrosisIdiopathic pulmonary fibrosisPulmonary fibrosisFibroproliferative responseLung diseaseIdiopathic pulmonary fibrosis cohortsExpression of toll-like receptor 9Toll-like receptor 9 activationTransplant-free survivalExpression of MCP-1Cohort of patientsSlow clinical progressionFibrotic lung diseaseAccelerated disease courseFatal lung diseaseIP-10Pharmacodynamic endpointsPreclinical modelsDisease courseClinical progressionPlasma mtDNAMCP-1Receptor 9Mouse modelNoninvasive assessment of the lung inflammation-fibrosis axis by targeted imaging of CMKLR1
Mannes P, Adams T, Farsijani S, Barnes C, Latoche J, Day K, Nedrow J, Ahangari F, Kaminski N, Lee J, Tavakoli S. Noninvasive assessment of the lung inflammation-fibrosis axis by targeted imaging of CMKLR1. Science Advances 2024, 10: eadm9817. PMID: 38896611, PMCID: PMC11186491, DOI: 10.1126/sciadv.adm9817.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisFibrotic lung diseaseRisk stratificationMurine modelLung fibrosisLung diseaseModel of bleomycin-induced lung fibrosisBleomycin-induced lung fibrosisImaging biomarkersMurine model of bleomycin-induced lung fibrosisBronchoalveolar lavage cellsMonocyte-derived macrophagesPositron emission tomographyInflammatory endotypesPulmonary fibrosisLavage cellsPoor survivalNoninvasive assessmentTherapeutic monitoringEmission tomographyCMKLR1FibrosisClinical trajectoryLungLung regions
2023
Vascular-Parenchymal Cross-Talk Promotes Lung Fibrosis through BMPR2 Signaling.
Yanagihara T, Tsubouchi K, Zhou Q, Chong M, Otsubo K, Isshiki T, Schupp J, Sato S, Scallan C, Upagupta C, Revill S, Ayoub A, Chong S, Dvorkin-Gheva A, Kaminski N, Tikkanen J, Keshavjee S, Paré G, Guignabert C, Ask K, Kolb M. Vascular-Parenchymal Cross-Talk Promotes Lung Fibrosis through BMPR2 Signaling. American Journal Of Respiratory And Critical Care Medicine 2023, 207: 1498-1514. PMID: 36917778, DOI: 10.1164/rccm.202109-2174oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisVascular smooth muscle cellsAdvanced idiopathic pulmonary fibrosisPulmonary hypertensionFibrotic lungsVascular remodelingEndothelial cellsPulmonary fibrosisLung diseaseLung fibrosisDevelopment of PHConcomitant pulmonary hypertensionProgressive lung scarringPulmonary vascular remodelingFibrotic lung diseaseProgression of fibrosisActivation of VSMCsActive TGF-β1Fatal lung diseaseSmooth muscle cellsWhole-exome sequencingLung scarringEndothelial dysfunctionPoor prognosisFibrogenic effects
2018
Evolving Genomics of Pulmonary Fibrosis
Ibarra G, Herazo-Maya J, Kaminski N. Evolving Genomics of Pulmonary Fibrosis. Respiratory Medicine 2018, 207-239. DOI: 10.1007/978-3-319-99975-3_9.Peer-Reviewed Original ResearchTranscript profiling approachesProfiling approachPotential drug targetsNonspecific interstitial pneumoniaIdiopathic pulmonary fibrosisFibrotic lung diseaseGenomic profiling studiesLung diseaseDrug targetsPulmonary fibrosisHypersensitivity pneumonitisKey moleculesProfiling studiesCells of patientsUnbiased viewDifferent interstitial lung diseasesInterstitial lung diseaseInterstitial pneumoniaLung fibrosisAnimal modelsTranscriptomeCellsGenomicsFibrosisDiseaseImpact of Transcriptomics on Our Understanding of Pulmonary Fibrosis
Vukmirovic M, Kaminski N. Impact of Transcriptomics on Our Understanding of Pulmonary Fibrosis. Frontiers In Medicine 2018, 5: 87. PMID: 29670881, PMCID: PMC5894436, DOI: 10.3389/fmed.2018.00087.Peer-Reviewed Original ResearchTranscriptomic studiesImpact of transcriptomicsGenome-scale profilingSingle-cell RNAseqRole of microRNAsIdiopathic pulmonary fibrosisNovel genesTranscriptomic analysisEpithelial genesIPF lungsRNA transcriptsDevelopmental pathwaysWnt pathwayBulk tissueMolecular analysisPulmonary fibrosisSpatial heterogeneityAnimal modelsTranscriptomicsGenesLethal fibrotic lung diseaseHuman IPF lungsImpact of lungPathwayFibrotic lung disease
2013
Evolving Genomics of Pulmonary Fibrosis
Herazo-Maya J, Kaminski N. Evolving Genomics of Pulmonary Fibrosis. Respiratory Medicine 2013, 379-402. DOI: 10.1007/978-1-62703-682-5_19.Peer-Reviewed Original ResearchTranscript profiling approachesProfiling approachField of genomicsNonspecific interstitial pneumoniaFibrotic lung diseasePotential drug targetsLung diseaseGenomic profiling studiesHypersensitivity pneumonitisDrug targetsKey moleculesProfiling studiesDifferent interstitial lung diseasesCells of patientsUnbiased viewGenomicsInterstitial lung diseaseStudy of lungInterstitial pneumoniaPulmonary fibrosisLung fibrosisAnimal modelsTranscriptomeCellsDiseasemiR-199a-5p Is Upregulated during Fibrogenic Response to Tissue Injury and Mediates TGFbeta-Induced Lung Fibroblast Activation by Targeting Caveolin-1
Cardenas C, Henaoui IS, Courcot E, Roderburg C, Cauffiez C, Aubert S, Copin MC, Wallaert B, Glowacki F, Dewaeles E, Milosevic J, Maurizio J, Tedrow J, Marcet B, Lo-Guidice JM, Kaminski N, Barbry P, Luedde T, Perrais M, Mari B, Pottier N. miR-199a-5p Is Upregulated during Fibrogenic Response to Tissue Injury and Mediates TGFbeta-Induced Lung Fibroblast Activation by Targeting Caveolin-1. PLOS Genetics 2013, 9: e1003291. PMID: 23459460, PMCID: PMC3573122, DOI: 10.1371/journal.pgen.1003291.Peer-Reviewed Original ResearchConceptsIdiopathic formMiR-199aIPF patientsMouse modelUnilateral ureteral obstruction (UUO) mouse modelLung fibroblastsFibrotic lung diseaseLung fibroblast activationBile duct ligationPoor response ratesNew therapeutic strategiesCultured lung fibroblastsDifferent mouse strainsKey cell typesPulmonary expressionHistologic featuresPulmonary fibrosisFibroblastic fociLung diseaseLung fibrosisCurrent therapiesFibrogenic responseKidney fibrosisLiver fibrosisBleomycin exposure
2012
Personalized medicine: applying omics to lung fibrosis
Herazo-Maya JD, Kaminski N. Personalized medicine: applying omics to lung fibrosis. Biomarkers In Medicine 2012, 6: 529-540. PMID: 22917154, PMCID: PMC3517740, DOI: 10.2217/bmm.12.38.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisFibrotic lung diseaseLung transplantPulmonary fibrosisLung fibrosisLung diseaseUnknown etiologyChronic diseasesSporadic formsHigh mortalityPatient careTreatment of diseasesDrug studiesCost-effective strategyDiseaseFibrosisDiagnosisPersonalized medicinePatientsTransplantEtiologyTherapyMortalityCarePrevention
2011
MicroRNAs in idiopathic pulmonary fibrosis
Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Translational Research 2011, 157: 191-199. PMID: 21420029, DOI: 10.1016/j.trsl.2011.01.012.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisIPF lungsPulmonary fibrosisLung fibrosisMiR-155Vascular endothelial growth factor (VEGF) pathwayEndothelial growth factor pathwayLethal fibrotic lung diseaseFibrotic lung diseaseMiR-29Upregulated miR-155Growth factor-β1Epithelial-mesenchymal transitionGrowth factor pathwaysLung epithelial cellsLung diseaseProfibrotic effectsBleomycin modelRole of microRNAsTherapeutic targetFactor-β1FibrosisMesenchymal transitionFactor pathwayLet-7 family members
2010
miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis
Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, Kaminski N, Abraham E. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. Journal Of Experimental Medicine 2010, 207: 1589-1597. PMID: 20643828, PMCID: PMC2916139, DOI: 10.1084/jem.20100035.Peer-Reviewed Original ResearchMeSH KeywordsActinsAnimalsAntisense Elements (Genetics)BleomycinCell LineCollagenExtracellular Matrix ProteinsFibroblastsFibronectinsGene ExpressionHumansIdiopathic Pulmonary FibrosisLungMiceMice, Inbred C57BLMice, TransgenicMicroRNAsOligonucleotidesPhosphorylationPulmonary FibrosisSmad2 ProteinSmad7 ProteinTransforming Growth Factor beta1ConceptsIdiopathic pulmonary fibrosisFibrotic lung diseaseMiR-21 expressionMiR-21Fibrotic diseasesLung diseaseLung fibrosisPulmonary fibroblastsPrimary pulmonary fibroblastsPro-fibrogenic activityLungs of patientsLungs of miceExperimental lung fibrosisMiR-21 levelsPulmonary injuryInjury contributesPulmonary fibrosisPathological mediatorsPathophysiologic processesDysregulation of miRNAsFibrogenic activationFibrosisDiseaseExtracellular matrix productionFatal processInhibition and Role of let-7d in Idiopathic Pulmonary Fibrosis
Pandit KV, Corcoran D, Yousef H, Yarlagadda M, Tzouvelekis A, Gibson KF, Konishi K, Yousem SA, Singh M, Handley D, Richards T, Selman M, Watkins SC, Pardo A, Ben-Yehudah A, Bouros D, Eickelberg O, Ray P, Benos PV, Kaminski N. Inhibition and Role of let-7d in Idiopathic Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2010, 182: 220-229. PMID: 20395557, PMCID: PMC2913236, DOI: 10.1164/rccm.200911-1698oc.Peer-Reviewed Original ResearchMeSH KeywordsActinsAnimalsCadherinsCells, CulturedDown-RegulationEpithelial CellsHMGA2 ProteinHumansIdiopathic Pulmonary FibrosisIn Situ HybridizationLungMiceMice, Inbred C57BLMicroRNAsPolymerase Chain ReactionPulmonary AlveoliS100 Calcium-Binding Protein A4S100 ProteinsSmad3 ProteinTransforming Growth Factor betaVimentinConceptsIdiopathic pulmonary fibrosisReal-time polymerase chain reactionQuantitative real-time polymerase chain reactionAlveolar epithelial cellsIPF lungsPulmonary fibrosisPolymerase chain reactionLet-7dEpithelial cellsLethal fibrotic lung diseaseAlpha-smooth muscle actinAlveolar septal thickeningMesenchymal markers N-cadherinFibrotic lung diseaseChain reactionLet-7d expressionSeptal thickeningPulmonary functionLung diseaseLung fibrosisEpithelial cell lineIntratracheal administrationIPF tissueProfibrotic effectsClinical trials
2008
MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis
Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, MacDonald SD, Pardo A, Sciurba F, Dauber J, Selman M, Gochuico BR, Kaminski N. MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis. PLOS Medicine 2008, 5: e93. PMID: 18447576, PMCID: PMC2346504, DOI: 10.1371/journal.pmed.0050093.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisInterstitial lung diseaseSubclinical interstitial lung diseasePulmonary fibrosisLung diseaseIPF patientsChronic progressive fibrotic lung diseaseControl individualsAsymptomatic interstitial lung diseaseProgressive fibrotic lung diseaseChronic obstructive pulmonary diseasePotential peripheral blood biomarkerChronic hypersensitivity pneumonitisPeripheral blood biomarkersChronic lung diseaseObstructive pulmonary diseaseFibrotic lung diseaseBronchoalveolar lavage fluidIndependent validation cohortFamilial pulmonary fibrosisProtein signaturesPulmonary diseaseSubstantial morbidityHypersensitivity pneumonitisLavage fluid